In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM

World J Gastroenterol. 2015 Feb 14;21(6):1784-93. doi: 10.3748/wjg.v21.i6.1784.

Abstract

Aim: To study the formation of intracellular glyceraldehyde-derived advanced glycation end products (Glycer-AGEs) in the presence of high concentrations of fructose.

Methods: Cells of the human hepatocyte cell line Hep3B were incubated with or without fructose for five days, and the corresponding cell lysates were separated by two-dimensional gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Glycer-AGEs were detected with the anti-Glycer-AGEs antibody. Furthermore, the identification of the proteins that are modified by glyceraldehyde in the presence of high concentrations of fructose was conducted using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The protein and mRNA levels were determined by Western blotting and real-time reverse transcription PCR, respectively.

Results: The results of the two-dimensional gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated a greater amount of Glycer-AGEs in the sample exposed to high concentrations of fructose than in the control. The detected Glycer-AGEs showed isoelectric points in the range of 8.0-9.0 and molecular weights in the range of 60-80 kDa. The heterogeneous nuclear ribonucleoprotein M (hnRNPM), which plays an important role in regulating gene expression by processing heterogeneous nuclear RNAs to form mature mRNAs, was identified as a modified protein using MALDI-TOF-MS. Increasing the concentration of fructose in the medium induced a concentration-dependent increase in the generated Glycer-AGEs. Furthermore, in an experiment using glyceraldehyde, which is a precursor of Glycer-AGEs, hnRNPM was found to be more easily glycated than the other proteins.

Conclusion: The results suggest that glyceraldehyde-modified hnRNPM alters gene expression. This change may cause adverse effects in hepatocytes and may serve as a target for therapeutic intervention.

Keywords: Advanced glycation end-products; Fructose; Glycation; Glyceraldehyde; Heterogeneous nuclear ribonucleoprotein M; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Dose-Response Relationship, Drug
  • Fructose / pharmacology
  • Glycation End Products, Advanced / metabolism
  • Glyceraldehyde / metabolism
  • Glycosylation
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism*
  • Heterogeneous-Nuclear Ribonucleoprotein Group M / genetics
  • Heterogeneous-Nuclear Ribonucleoprotein Group M / metabolism*
  • Humans
  • Liver / drug effects
  • Liver / metabolism*
  • Non-alcoholic Fatty Liver Disease / genetics
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Proteomics / methods

Substances

  • Glycation End Products, Advanced
  • HNRNPM protein, human
  • Heterogeneous-Nuclear Ribonucleoprotein Group M
  • Fructose
  • Glyceraldehyde